BioVie Inc. (NasdaqCM: BIVI)
Health Care · Biotechnology · US
$1.20
-13.67% today · -39.7% 1Y
BioVie Inc. (NasdaqCM: BIVI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $9.05M and employs 13 people.
Over the last twelve months the share price has lost 39.7%, trading between 0.82 and 3.79.
Tweenvest scores BioVie Inc. across four factors: quality 35/100, value 28/100. Its strongest factor is quality.
BIVI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $9.05M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.05
- Dividend yield
- —
- Beta (5Y)
- 0.73
- 52-week high
- $3.79
- 52-week low
- $0.82
- Avg volume (3M)
- —
- Shares outstanding
- 7.54M
- Employees
- 13
- Next earnings
- —
About BioVie Inc.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
- ISIN
- US09074F5044
- Founded
- 2013
- Listed since
- Sep 18, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Lisata Therapeutics, Inc.NasdaqCM: LSTA | $9.28M | $1.03 | -2.83% |
| Celestra Inc.KOSDAQ: A352770 | $9.28M | ₩— | — |
| Cambium Bio LimitedASX: CMB | $9.22M | AU$0.45 | -16.67% |
| Spago Nanomedical AB (publ)OM: SPAGO | $9.19M | Skr0.11 | +12.32% |
| Hemostemix Inc.TSXV: HEM | $8.97M | CA$0.06 | -20.00% |
| Poxel S.A.ENXTPA: POXEL | $8.95M | €0.15 | +10.45% |
| AdAlta LimitedASX: 1AD | $8.94M | AU$0.00 | +14.29% |
| Biovica International AB (publ)OM: BIOVIC B | $8.90M | Skr0.30 | -0.33% |
Figures last refreshed Oct 18, 2026.